知识产权

港股IPO招股书披露先例 · 24 家公司,27 项

知识产权事项一般指专利、商标、版权等侵权诉讼及调查、权属或转让登记争议等纠纷。招股书通常在概要、风险因素、业务及财务资料章节披露诉讼进展、涉诉产品收入占比、已计提拨备及法律顾问或董事对重大性的评估;已和解的个案多说明和解安排、无侵权认定及收入合规情况,未决事项则辅以中止程序、计提拨备或完成权利登记等处理。

合规类事项自 2026 年 8 月 24 日起递交的文件开始收录。

2026-09-28PHIP不合规事项
安徽希磁科技股份有限公司Anhui Sinomags Technology Co., Ltd

25项专利被提起无效宣告请求

During the Track Record Period, the Petitioner had filed patent invalidation proceedings against 25 patents (the "Disputed Patents").

Business · 第 182 页

However, following examination of materials submitted by the Petitioner, the Patent Re-examination Department declared 20 patents invalid and two patents partially invalid primarily on the basis of lack of inventiveness.

Business · 第 183 页

for two of such patents, the Patent Re-examination Department’s decision declaring the patents invalid was upheld by the Beijing Intellectual Property Court at first instance, following which we filed appeals to the Supreme People’s Court, and such appeals remained pending as of the Latest Practicable Date

Business · 第 183 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-09-28Prospectus合规确认
北京奕斯伟计算技术股份有限公司Beijing ESWIN Computing Technology Co., Ltd.01256.HK

部分项目开源许可义务之适用分析

Approximately 10.6% of these projects were subject to obligations arising from the relevant open-source software licenses, which require that if we modify certain software components, the modified source code must also be open sourced.

Business · 第 160 页

Accordingly, such partial software open-source obligations will not result in negative impact on our research and development, production, or business operations, nor will they lead to the leakage of our technological secrets or impairment of our intellectual property rights.

Business · 第 160 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-09-25PHIP不合规事项
深圳传音控股股份有限公司Shenzhen Transsion Holdings Co., Ltd.

未经授权使用工业设计软件被判赔偿

For example, we were involved in a copyright infringement proceeding commenced by PTC Inc. in 2024 in relation to the alleged unauthorized use of certain industrial design software.

Business · 第 164 页

In August 2026, the Chongqing High People’s Court rendered its final judgment, ordering us to pay economic damages of approximately RMB9.6 million and litigation costs and other expenses of approximately RMB0.5 million.

Business · 第 164 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-09-25PHIP不合规事项
深圳传音控股股份有限公司Shenzhen Transsion Holdings Co., Ltd.

涉71宗标准必要专利纠纷及多国诉讼

During the Track Record Period and up to the date of this document, we were involved in an aggregate of 71 SEP-related disputes with 12 SEP holders, of which 62 had been settled in relation to nine SEP holders.

Business · 第 167 页

Such preliminary injunction took effect and remained in force as of the Latest Practicable Date.

Business · 第 169 页

As of December 31, 2023, 2024 and 2025 and April 30, 2026, the provisions made for SEP-related disputes amounted to RMB2,390.2 million, RMB900.9 million, RMB1,030.9 million and RMB1,224.9 million, respectively.

Business · 第 172 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-09-23Application Proof合规确认

职务发明专利及软件著作权归属合法

Our PRC Legal Advisor is of the view that the Group has lawful ownership of, or valid rights to use, and is not subject to any pledge, mortgage, security or other material restrictions of, such patents and software copyrights.

Business · 第 155 页

These intellectual properties were developed by Mr. Zhu in the course of his employment with us and constitute service inventions and service works under applicable laws, with title vesting in the Group and no co-inventorship arising between Mr. Zhu and the Group.

Business · 第 155 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-09-14Prospectus合规确认
深圳四方精创资讯股份有限公司Shenzhen Forms Syntron Information Co., Ltd.06700.HK

开源软件使用符合许可条款

During the Track Record Period and up to the Latest Practicable Date, we confirm that we have utilized open-source software in the PRC in compliance with the relevant license terms as follows: (a) our use is limited to compression, development, database and debugging tools as auxiliary development tools, without any modification, resale, lease or secondary distribution

Business · 第 153 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-09-11Application Proof合规确认
翱捷科技股份有限公司ASR MICROELECTRONICS CO., LTD.

知识产权法律法规合规之确认

As advised by our PRC Legal Advisor, during the Track Record Period and up to the Latest Practicable Date, we had complied with all PRC applicable intellectual property laws and regulations in all material respects.

Business · 第 156 页

As of June 30, 2026, we had 246 registered patents, 46 trademarks, 21 software copyrights, 161 integrated circuit layout design rights and one domain name registered in the PRC.

Business · 第 156 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-09-10Application Proof不合规事项
广东微电新能源股份有限公司Guangdong Mic-Power New Energy Co., Ltd.

与VARTA的历史专利诉讼(已和解)

Between 2020 and 2022, we were involved in patent proceedings in the U.S. and China with VARTA Microbattery GmbH (“VARTA”) in relation to certain historical models of partially sealed metal-casing button batteries (the “Patent Proceedings”).

Business · 第 197 页

As advised by the Company’s U.S. Legal Advisor, on the basis that (i) the relevant settlement arrangements were entered into to resolve the Patent Proceedings, pursuant to which the parties mutually released each other from past claims and liabilities and covenanted not to sue; (ii) the related proceedings have been dismissed with prejudice or otherwise withdrawn; and (iii) we have not received any further claim, demand or proceeding from VARTA since the settlement and up to the Latest Practicable Date, the Patent Proceedings have been fully and finally resolved, and the likelihood of any re-opening of such historical claims by VARTA against us is low.

Business · 第 197 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-09-07PHIP不合规事项
浙江涛涛车业股份有限公司Zhejiang Taotao Vehicles Co., Ltd.

Golabs涉美国ITC 337专利侵权调查

In January 2025, Razor USA LLC and Shane Chen filed a complaint with the ITC under Section 337 of the Tariff Act of 1930 against multiple respondents, including Golabs, alleging that certain GOTRAX branded electric balance bikes (the “Relevant Products”), infringed U.S. Reissue Patent Nos. RE46,964 and RE49,608 (collectively, the “Asserted Utility Patents”) and U.S. Design Patent No. D739,906 (the “Asserted Design Patent” and, together with the Asserted Utility Patents, the “Asserted Patents”).

Business · 第 180 页

As of December 2025, the complainant withdrew its design patent infringement allegations. The settlement conference was not held and the case remains under review by the ITC as of the Latest Practicable Date.

Risk Factors · 第 34 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-08-31Prospectus不合规事项
深圳市江波龙电子股份有限公司Shenzhen Longsys Electronics Co., Ltd.09976.HK

Micron于欧洲多地对集团提起专利侵权诉讼

As of the Latest Practicable Date, we were involved in certain patent infringement proceedings initiated by Micron Technology, Inc. (“Micron”), one of our top suppliers during the Track Record Period, alleging that, inter alia, certain NAND flash memory dies and SSD products sold by us and other named defendants in Germany, France and the United Kingdom infringe certain European patents of the claimant (the “IP Proceedings”), where Yangtze Memory Technologie Co., Ltd. (“YMTC”), our another top supplier during the Track Record Period, is the manufacturer of the litigation-related memory dies that are incorporated into the accused products sold by us.

Risk Factors · 第 53 页

On July 14, 2026, Micron filed a Statement of Claim before the Local Division Mannheim of the Unified Patent Court (“UPC”) (docket no. UPC_CFI_2556/2026) alleging that, inter alia, certain NAND flash memory dies and SSD products sold by Lexar Europe B.V. (“Lexar Europe”), one of the named defendants and a subsidiary of the Company, and other named defendants in Germany and France infringe European patent EP 2745295B1 (“EP’295”).

Business · 第 216 页

it is noted that solely based on the Statement of Claim, Micron has provisionally estimated the value of the action to be EUR 2,000,000 and EUR 1,000,000 in relation to the Micron UPC Europe Lawsuit and the Micron Munich Lawsuit, respectively.

Business · 第 218 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-08-31Application Proof合规确认
普莱医药(江苏)股份有限公司ProteLight Pharmaceuticals (Jiangsu) Co., Ltd.

FTO分析:实施核心技术无重大专利侵权风险

According to the freedom-to-operate (“FTO”) search and analysis conducted by our IP counsel on our Core Product and key products in China and U.S., our Directors and our IP counsel believe that (i) we can implement the product technology of all of Core Product and key products in China and U.S. without any material risk of patent infringement; (ii) given that we do not have plan to commercialize our Core Product in Australia as of the Latest Practicable Date, our Directors are of the view that the FTO search and analysis in China and the U.S. should be sufficient to prevent potential risks in relation to the infringements of IP rights.

Business · 第 203 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-08-31Prospectus合规确认
优地机器人(无锡)股份有限公司Excelland Robotics (Wuxi) Co. Ltd.03231.HK

对视觉感知算法的使用无重大法律障碍

As advised by our PRC Legal Adviser, under the relevant agreements and statement, although our rights are non-exclusive, we have rights to use the Vision Perception Algorithm, source code and SDK software.

Business · 第 175 页

As further advised by our PRC Legal Adviser, there is no material legal impediment to our Group's use of the Vision Perception Algorithm and the related source code.

Business · 第 175 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-08-30Application Proof不合规事项
杭州邦顺制药股份有限公司Hangzhou Bangshun Pharmaceutical Co., Ltd.

部分境外司法权区专利转让登记尚未完成

In certain less important jurisdictions, the registration process remains ongoing due to time-consuming administrative procedures.

Business · 第 189 页

For the remaining jurisdictions, namely Italy and Spain, the transfer is expected to be completed by the fourth quarter of 2026.

Business · 第 189 页

Dr. Yin remains recorded as a co-owner of certain patent rights of the Core Products in certain jurisdictions solely because those patents are registered in jurisdictions outside the PRC, for which the registration of the transfer is pending completion as described above.

Business · 第 189 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-08-30Application Proof合规确认
杭州邦顺制药股份有限公司Hangzhou Bangshun Pharmaceutical Co., Ltd.

自由实施分析确认未侵犯第三方知识产权

Moreover, based on the results of the Freedom-to-Operate (“FTO”) analysis, our IP Legal Adviser and Directors are of the opinion that, in relation to the chemical molecular structures currently being developed for our Core Products, no third-party patents exist in the PRC or the U.S. that would reasonably be expected to impede the commercialization of such products, and that we have not infringed any valid and enforceable patents or other intellectual property rights of any third party.

Business · 第 190 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-08-28Application Proof不合规事项

上海嘉因提起商标侵权及不正当竞争诉讼

On March 27, 2026, Shanghai Jiayin Biotechnology Co., Ltd.(上海嘉因生物科技有限公司) (the “Shanghai Jiayin”) filed a lawsuit with the Intermediate People's Court of Suzhou Municipality, Jiangsu Province (the “Suzhou Court”), alleging that the inclusion of the words “嘉因” and “嘉因生物” in the enterprise name of Hangzhou Jiayin constitutes trademark infringement and unfair competition, and seeking damages of RMB60.0 million.

Business · 第 207 页

On July 13, 2026, we submitted an objection to jurisdiction to the Suzhou Court, requesting that the case be transferred to the Intermediate People's Court of Hangzhou Municipality for trial.

Business · 第 207 页

Our PRC legal adviser with respect to intellectual property laws in the PRC is of the view that the infringement claims asserted by Shanghai Jiayin are without merit, and that the risk of our being required to pay RMB60.0 million in damages in connection with such alleged infringement is remote.

Business · 第 207 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-08-28Application Proof合规确认

自由实施分析未发现侵犯第三方专利

Based on the FTO Analysis, our Directors are of the view that there are no valid and enforceable patents of any third party in China and the U.S. covering the amino acid sequences or indications currently under development of our Core Products and we have not infringed any valid and enforceable patents or other IP rights of any third parties.

Business · 第 212 页

No valid claims of third party patents in the U.S. and the PRC that are infringed by FT-002 or FT-003 have been identified.

Business · 第 211 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看

Tell us